In a temporary break from its corporate drama, Sinovac posted positive topline data from a phase 3 study of its chickenpox vaccine.
Serum Institute of India has new results from a phase 3 trial of its rotavirus vaccine as it preps to deliver millions of doses.
AstraZeneca rolled out positive results for a LAMA/LABA that could help the company gain a respiratory foothold in Asia.
Amid a wave of pricing pressure and consolidation in the generics industry, another sale is brewing.
Gilead Sciences has received approval for Sovaldi from China's FDA, gaining a foothold in the world's largest hepatitis C market.
Not all Big Pharma's businesses in emerging markets are doing so well, Fosun is buying a smaller stake in Gland, Taiho and Arcus ink cancer option deal.
South Korean drug manufacturer Firson was slapped with a warning letter and placed on an import alert by the FDA.
Big Pharma expanded in emerging markets by 6.1% last quarter, but GSK and Eli Lilly didn't reap as much growth as their peers
Fosun Pharma has cut back its offer for Gland Pharma just enough to circumvent the Indian government’s scrutiny.
WuXi NextCODE has raised $240 million in series B, FDA slapped Celltrion with a long Form 483, Biocon's $275 million insulin plant opened shop.